Seeking Alpha

Astex Pharmaceutical takes another leg higher on positive Phase II trial results for SGI-110

  • Astex Pharmaceutical (ASTX) continues to run, now up more than 23% following positive topline results from Phase II trials of its SGI-110 drug candidate in patients with acute myelogenous leukemia and myelodysplastic syndromes.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector